Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Quick Search
My eDoc
Session History
Support Wiki
Direct access to
document ID:

          Institute: MPI für molekulare Biomedizin     Collection: Jahrbuch 2017 (publ. 2016, arch)     Display Documents

ID: 732125.0, MPI für molekulare Biomedizin / Jahrbuch 2017 (publ. 2016, arch)
Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction
Authors:Malan, D.; Zhang, M.; Stallmeyer, B.; Muller, J.; Fleischmann, B. K.; Schulze-Bahr, E.; Sasse, P.; Greber, B.
Date of Publication (YYYY-MM-DD):2016-03
Title of Journal:Basic Res Cardiol
Issue / Number:2
Start Page:14
Review Status:Internal review
Audience:Not Specified
Abstract / Description:Long QT syndrome is a potentially life-threatening disease characterized by delayed repolarization of cardiomyocytes, QT interval prolongation in the electrocardiogram, and a high risk for sudden cardiac death caused by ventricular arrhythmia. The genetic type 3 of this syndrome (LQT3) is caused by gain-of-function mutations in the SCN5A cardiac sodium channel gene which mediates the fast Nav1.5 current during action potential initiation. Here, we report the analysis of LQT3 human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). These were generated from a patient with a heterozygous p.R1644H mutation in SCN5A known to interfere with fast channel inactivation. LQT3 hiPSC-CMs recapitulated pathognomonic electrophysiological features of the disease, such as an accelerated recovery from inactivation of sodium currents as well as action potential prolongation, especially at low stimulation rates. In addition, unlike previously described LQT3 hiPSC models, we observed a high incidence of early after depolarizations (EADs) which is a trigger mechanism for arrhythmia in LQT3. Administration of specific sodium channel inhibitors was found to shorten action and field potential durations specifically in LQT3 hiPSC-CMs and antagonized EADs in a dose-dependent manner. These findings were in full agreement with the pharmacological response profile of the underlying patient and of other patients from the same family. Thus, our data demonstrate the utility of patient-specific LQT3 hiPSCs for assessing pharmacological responses to putative drugs and for improving treatment efficacies.
Free Keywords:Cardiac disease modeling; Drug testing; Human iPS cells; Type 3 long-QT syndrome
External Publication Status:published
Document Type:Article
Communicated by:Jeanine Müller-Keuker
Affiliations:MPI für molekulare Biomedizin
External Affiliations:Human Stem Cell Pluripotency Group, Max Planck Institute for Molecular Biomedicine, 48149, Munster, Germany. Chemical Genomics Centre of the Max Planck Society, 44227, Dortmund, Germany. Department of Cardiovascular Medicine, Institute for Genetics of Heart Diseases (IfGH), University Hospital Munster, 48149, Munster, Germany. Institute of Physiology I, Life & Brain Center, University of Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany. philipp.sasse@uni-bonn.de. Human Stem Cell Pluripotency Group, Max Planck Institute for Molecular Biomedicine, 48149, Munster, Germany. boris.greber@mpi-muenster.mpg.de. Chemical Genomics Centre of the Max Planck Society, 44227, Dortmund, Germany. boris.greber@mpi-muenster.mpg.de.
Identifiers:ISSN:1435-1803 (Electronic) 0300-8428 (Linking) %R 10.1... [ID No:1]
URL:http://www.ncbi.nlm.nih.gov/pubmed/26803770 [ID No:2]
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.